Access Pharmaceuticals Receives Initial MuGard Prescriptions and Reimbursements

Company Reaches Critical Milestone In North American MuGard Commercialization Process

Oct 15, 2010, 10:57 ET from Access Pharmaceuticals, Inc.

DALLAS and NEW YORK, Oct. 15 /PRNewswire/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.  In addition, the Company has received reimbursement for the prescriptions from leading health care providers. Through its consultants and specialty distribution partner, Access' outreach to payor networks for MuGard prescription reimbursement is ongoing.

"Receiving the first MuGard prescriptions marks a major milestone in our Company's effort in bringing MuGard to the North American cancer supportive care market," said Frank Jacobucci, VP of Sales and Marketing for Access Pharmaceuticals, Inc.  He continued, "We aimed to align reimbursement, a critical component of our commercialization strategy, with the official launch of MuGard in the US and we are pleased with our team's timely progress.  As we continue executing on our comprehensive strategy to solidify various reimbursement verticals, we look forward to keeping the medical and investment community updated."

About MuGard:

MuGard is a novel; ready-to-use and safe-to-swallow mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.  For more information, including product testimonials, please visit www.MuGard.com.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase II clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and Cobalamin-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.

Contact: Company

Contact: Investor Relations

Christine Berni

Donald C. Weinberger/Diana Bittner (media)

Director of Investor Relations

Wolfe Axelrod Weinberger Assoc. LLC

Access Pharmaceuticals, Inc.

(212) 370-4500

(212) 786-6208

SOURCE Access Pharmaceuticals, Inc.



RELATED LINKS

http://www.accesspharma.com


http://www.MuGard.com